COVID-19 vaccination in Turkey

Last updated
COVID-19 vaccination in Turkey
Date14 January 2021 (2021-01-14) – present
LocationTurkey
Cause COVID-19 pandemic
TargetFull immunisation of people in Turkey against COVID-19
Participants49.543.627 people completely vaccinated (12 November 2021) [1]
Website covid19asi.saglik.gov.tr

The COVID-19 vaccination campaign in Turkey began on 14 January 2021. [2] As of 12 November 2021, 55.789.131 people have received their first dose, and 49.543.627 people have been fully vaccinated. [1]

Contents

Vaccines on order

There are several COVID-19 vaccines at various stages of development around the world. Turkey currently uses 3 different vaccines. [3] [4]

VaccineApprovalDeployment
Pfizer–BioNTech Green check.svgGreen check.svg
Sinovac Green check.svgGreen check.svg
Sputnik V Green check.svgGreen check.svg
TurkoVac PendingDark Red x.svg

Vaccination statistics

  New vaccination per day  7-day moving average

  First dose  Second dose

  First dose  Second dose

Related Research Articles

Oxford–AstraZeneca COVID-19 vaccine Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.

CoronaVac Vaccine against COVID-19

CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.

Sinopharm BIBP COVID-19 vaccine Vaccine against COVID-19

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.

COVID-19 vaccination in the United Kingdom Immunisation against COVID-19

The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom. The UK's vaccination rollout was the world's first mass immunisation programme for the disease when it began on 8 December 2020 after Margaret Keenan received her first dose of two. As of 6 October 2021, 49,068,705 first doses and 45,078,529 second doses of a vaccine had been administered across the UK.

The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Sweden

Vaccination against COVID-19 in Sweden started on 27 December 2020 after the approval of the Pfizer–BioNTech vaccine by the European Commission. In Sweden, the Public Health Agency has been commissioned by the government to create a vaccination plan. Sveriges riksbank, the central bank of Sweden, predicts that efficient vaccination against COVID-19 has macroeconomic benefits. As of 1 September 2021, 82.0% of adults in Sweden have received at least one dose, with a total of 12,700,896 administered.

COVID-19 vaccination in India Immunisation programme against COVID-19 in India

India began administration of COVID-19 vaccines on 16 January 2021. As of 27 November 2021, India has administered over 1.21 billion doses overall, including first and second doses of the currently-approved vaccines. In India,80% of the eligible population received at least one shot, and number of fully vaccinated has surpassed those who have partially jabbed.

COVID-19 vaccination in Australia Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.

COVID-19 vaccination in Albania

The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.

COVID-19 vaccination in the Republic of Ireland Immunisation plan against COVID-19

The COVID-19 vaccination programme in the Republic of Ireland is an ongoing mass immunisation campaign that began on 29 December 2020 in response to the COVID-19 pandemic in the Republic of Ireland. Ireland's vaccination rollout has been praised as one of the most successful rollouts in the world and was ranked number one in the European Union in terms of its percentage of adult population fully vaccinated.

COVID-19 vaccination in Zimbabwe

On 22 February 2021, Zimbabwe launched their national COVID-19 vaccination program using the Sinopharm BIBP vaccine. As of 26 November 2021, 3,756,498 people have received their first dose, and 2,786,979 people have received their second dose.

COVID-19 vaccination in New Zealand Ongoing COVID-19 vaccine programme in New Zealand

COVID-19 vaccination in New Zealand began on 20 February 2021, and will continue throughout the year with the goal of vaccinating all willing New Zealanders aged 12+. As of 1 September, anyone in New Zealand is eligible to be vaccinated.

COVID-19 vaccination in Africa Immunisation programme against COVID-19 in Africa

COVID-19 vaccination programs have begun in many countries and territories in Africa. As of 5 July 2021, vaccination campaigns had started in 51 African countries with 36.5 million people receiving at least one dose.

COVID-19 vaccination in Ghana

COVID-19 vaccination in Ghana began on Monday 1 March 2021 after the country became the first recipient of the Oxford-AstraZeneca COVID-19 vaccine as part of the COVAX initiative. As of 6 June 2021, Ghana has administered 1,230,000 vaccine doses.

COVID-19 vaccination in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

COVID-19 vaccination in Germany

The COVID-19 vaccination campaign in Germany began on 26 December 2020. As of 19 September 2021, 55,869,314 people have received at least one dose, while 52,503,166 people have been fully vaccinated.

COVID-19 vaccination in Singapore Plan to immunize against COVID-19

COVID-19 vaccination in Singapore is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Cameroon is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

The COVID-19 vaccination campaign began in Fiji on the first quarter of 2021 and will continue throughout the year with the goal of vaccinating all eligible Fijians. The government has made it mandatory for all eligible adults to take the COVID-19 vaccines.

References

  1. 1 2 "COVID-19 Aşisi Bilgilendirme Platformu" [COVID-19 Vaccine Information Platform]. Turkish Ministry of Health.
  2. "Turkey begins mass COVID-19 vaccination with Sinovac's jabs". Xinhua News Agency. 14 January 2021. Retrieved 1 July 2021.
  3. Tasdemir, Firat (2 April 2021). "1st doses of Pfizer-BioNTech jab administered in Turkey". Anadolu Agency.
  4. Aydogan, Merve (30 April 2021). "Turkey OKs emergency use of Sputnik-V vaccine". Anadolu Agency.